The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The Europe specialty generics market size reached US$ 16.8 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 28.1 Billion by 2027, exhibiting a growth rate (CAGR) of 8.86% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Specialty generics are classified as high-cost, high complexity and/or high touch generics. They are the generic versions of speciality branded drugs after they lose their patent protection. Specialty generics are used to treat complex diseases which may be chronic by nature and life-threatening like hepatitis C, cancer, rheumatoid arthritis, multiple sclerosis, etc.
Driven by factors such as an increasing aging population, changing lifestyles and a rising prevalence of chronic diseases, healthcare costs in Europe have increased significantly in recent years creating a huge burden on the government, healthcare providers and patients. Specialty generics are playing a major role in the region to reduce this cost burden as they are more cost-effective as compared to their branded versions. Unlike branded speciality drugs, specialty generics don’t require expensive and time-consuming research and development procedures. Additionally, they also don’t incur the same amount of marketing and promotional expenses, resulting in substantially lower costs. In addition to this, the patent expiration of several blockbuster specialty drugs is expected to expire in the coming years creating a positive impact on the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the Europe specialty generics market report, along with forecasts at the regional and country level from 2022-2027. Our report has categorized the market based on route of administration, indication and distribution channel.
Breakup by Region:
Breakup by Route of Administration:
Breakup by Indication:
Breakup by Distribution Channel:
The leading players in the European specialty generics industry have also been examined in the report.
|Base Year of the Analysis||2021|
|Segment Coverage||Route of Administration, Indication, Distribution Channel, Country|
|Countries Covered||Germany, France, United Kingdom, Italy, Spain, Rest of Europe|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at